Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 5/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | CCKBR | P32239 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.38 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.38 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3774280 | 1.00 | CACNA1B (0.43) | CACNA1BL3MBTL1CCKBRPDE4BHSD11B1 | |
| SCHEMBL13007477 | 0.86 | ALDH1A1 (0.42) | L3MBTL1TPSAB1TPSD1TPSG1 | |
| SCHEMBL3780890 | 0.81 | L3MBTL1 (0.34) | CACNA1BL3MBTL1HSD11B1 | |
| SCHEMBL3780913 | 0.81 | L3MBTL1 (0.34) | CACNA1BL3MBTL1HSD11B1 | |
| SCHEMBL3805536 | 0.81 | L3MBTL1 (0.34) | CACNA1BL3MBTL1HSD11B1 | |
| SCHEMBL13525248 | 0.81 | CACNA1B (0.41) | CACNA1BL3MBTL1KLK7KLK5CTSL | |
| SCHEMBL3572628 | 0.80 | CACNA1B (0.59) | CACNA1BCCKBRKLK7KLK5CTSL | |
| SCHEMBL191613 | 0.80 | CACNA1B (0.59) | CACNA1BCCKBRKLK7KLK5CTSL | |
| SCHEMBL1197947 | 0.80 | TPSAB1 (0.43) | L3MBTL1TPSAB1TPSD1TPSG1 | |
| SCHEMBL13397932 | 0.80 | TPSAB1 (0.43) | L3MBTL1TPSAB1TPSD1TPSG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9636409-B2 | Enzyme and receptor modulation using covalent conjugates of alpha,alpha-disubstituted glycine esters | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-05-02 | — | — | US | disclosed |
| US-20160151509-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20140088159-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LTD. (GB) | 2014-03-27 | — | — | US | disclosed |
| US-20100317865-A1 | ENZYME AND RECEPTOR MODULATION | c/o Chroma Therapeutics Ltd. (GB) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088159-A1 | ENZYME AND RECEPTOR MODULATION | CES1, GLRB, GLRA1 | CACNA1B 3409/4885L3MBTL1 3377/4885CCKBR 684/4885 |
| US-20160151509-A1 | ENZYME AND RECEPTOR MODULATION | CES1, GLRB, GLRA1 | CACNA1B 3409/4885L3MBTL1 3377/4885CCKBR 684/4885 |
| US-20100317865-A1 | ENZYME AND RECEPTOR MODULATION | CES1, GLRB, GLRA1 | CACNA1B 3409/4885L3MBTL1 3377/4885CCKBR 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.